Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 77
Filter
1.
Acta cir. bras ; 38: e384123, 2023. tab, ilus
Article in English | LILACS, VETINDEX | ID: biblio-1519878

ABSTRACT

Purpose: To study the uptake capacity of cells from the reticuloendothelial system after irradiation with high-energy X-rays. Methods: Eighteen male Wistar rats were distributed in three groups: group A (n = 6): control, unirradiated animals studied alongside animals from group B; group B (n = 6) and group C (n = 6): animals irradiated and studied after 24 and 48 hours, respectively. The rats were anesthetized and placed on a 10 MV linear accelerator. Next, they were irradiated in the abdominal region, with 8 Gy. Twenty-four (groups A and B) and 48 hours later (group C), a colloidal carbon solution (1 mL/kg) was intravenously injected in the tail vein. Fifty minutes later, the spleens and livers were withdrawn and prepared to be studied. Kupffer cells and splenic macrophages containing carbon pigments were counted in an optical microscope. Arithmetic means were calculated for each group and compared among them. Results: X-rays were associated with a reduced number of Kupffer cells containing colloidal carbon, proliferation and enlargement of biliary ducts, hypoplasia, and hepatocyte necrosis. In the irradiated spleen, the colloidal carbon uptake was concentrated in the marginal zone around the white pulp, with an inexpressive uptake of pigments by macrophages from white and red pulps. Conclusions: The X-rays in the rat abdomen are associated with a reduction in the Kupffer cells uptake of colloidal carbon, hepatocyte disorders, bile duct proliferation, and splenic uptake of colloidal carbon concentrated in the marginal zone.


Subject(s)
Animals , Rats , Mononuclear Phagocyte System , Radiotherapy, High-Energy , Kupffer Cells
2.
Braz. oral res. (Online) ; 30(1): e9, 2016. tab, graf
Article in English | LILACS | ID: lil-768256

ABSTRACT

Abstract Radiotherapy for malignancies in the head and neck can cause common complications that can result in tooth damage that are also known as radiation caries. The aim of this study was to examine damage to the surface topography and calculate changes in friction behavior and the nano-mechanical properties (elastic modulus, nanohardness and friction coefficient) of enamel and dentine from extracted human third molars caused by exposure to radiation. Enamel and dentine samples from 50 human third molars were randomly assigned to four test groups or a control group. The test groups were exposed to high energy X-rays at 2 Gy/day, 5 days/week for 5 days (10 Gy group), 15 days (30 Gy group), 25 days (50 Gy group), 35 days (70 Gy group); the control group was not exposed. The nanohardness, elastic modulus, and friction coefficient were analyzed using a Hysitron Triboindenter. The nano-mechanical properties of both enamel and dentine showed significant dose-response relationships. The nanohardness and elastic modulus were most variable between 30-50 Gy, while the friction coefficient was most variable between 0-10 Gy for dentine and 30-50 Gy for enamel. After exposure to X-rays, the fracture resistance of the teeth clearly decreased (rapidly increasing friction coefficient with increasing doses under the same load), and they were more fragile. These nano-mechanical changes in dental hard tissue may increase the susceptibility to caries. Radiotherapy caused nano-mechanical changes in dentine and enamel that were dose related. The key doses were 30-50 Gy and the key time points occurred during the 15th-25th days of treatment, which is when application of measures to prevent radiation caries should be considered.


Subject(s)
Humans , Dental Enamel/radiation effects , Dentin/radiation effects , Radiation Injuries/etiology , Radiotherapy, High-Energy/adverse effects , Analysis of Variance , Dental Caries/etiology , Dental Enamel/chemistry , Dentin/chemistry , Elastic Modulus/radiation effects , Friction/radiation effects , Hardness/radiation effects , Medical Illustration , Radiation Dosage , Reference Values , Surface Properties/radiation effects , Time Factors
3.
Chinese Journal of Cancer ; (12): 148-158, 2014.
Article in English | WPRIM | ID: wpr-320553

ABSTRACT

Tumor cell proliferation, infiltration, migration, and neovascularization are known causes of treatment resistance in glioblastoma multiforme (GBM). The purpose of this study was to determine the effect of radiation on the growth characteristics of primary human GBM developed in a nude rat. Primary GBM cells grown from explanted GBM tissues were implanted orthotopically in nude rats. Tumor growth was confirmed by magnetic resonance imaging on day 77 (baseline) after implantation. The rats underwent irradiation to a dose of 50 Gy delivered subcuratively on day 84 postimplantation (n = 8), or underwent no radiation (n = 8). Brain tissues were obtained on day 112 (nonirradiated) or day 133 (irradiated). Immunohistochemistry was performed to determine tumor cell proliferation (Ki-67) and to assess the expression of infiltration marker (matrix metalloproteinase-2, MMP-2) and cell migration marker (CD44). Tumor neovascularization was assessed by microvessel density using von-Willebrand factor (vWF) staining. Magnetic resonance imaging showed well-developed, infiltrative tumors in 11 weeks postimplantation. The proportion of Ki-67-positive cells in tumors undergoing radiation was (71 +/- 15)% compared with (25 +/- 12)% in the nonirradiated group (P = 0.02). The number of MMP-2-positive areas and proportion of CD44-positive cells were also high in tumors receiving radiation, indicating great invasion and infiltration. Microvessel density analysis did not show a significant difference between nonirradiated and irradiated tumors. Taken together, we found that subcurative radiation significantly increased proliferation, invasion, and migration of primary GBM. Our study provides insights into possible mechanisms of treatment resistance following radiation therapy for GBM.


Subject(s)
Animals , Female , Humans , Rats , Brain Neoplasms , Metabolism , Pathology , Radiotherapy , Cell Line, Tumor , Cell Movement , Radiation Effects , Cell Proliferation , Radiation Effects , Glioblastoma , Metabolism , Pathology , Radiotherapy , Hyaluronan Receptors , Metabolism , Immunohistochemistry , Ki-67 Antigen , Metabolism , Magnetic Resonance Imaging , Matrix Metalloproteinase 2 , Metabolism , Microvessels , Pathology , Neoplasm Transplantation , Neovascularization, Pathologic , Pathology , Radiation Tolerance , Radiotherapy, High-Energy , Rats, Nude
4.
Chinese Journal of Cancer ; (12): 283-288, 2013.
Article in English | WPRIM | ID: wpr-295841

ABSTRACT

The female sex is traditionally considered a favorable prognostic factor for nasopharyngeal carcinoma (NPC). However, no particular study has reported this phenomenon. To explore the prognostic impact of gender on patients with NPC after definitive radiotherapy, we reviewed the clinical data of 2063 consecutive patients treated between 1st January 2000 and 31st December 2003 in the Sun Yat-sen University Cancer Center. The median follow-up for the whole series was 81 months. The female and male patients with early stage disease comprised 49.4% and 28.1% of the patient population, respectively. Both the 5-year overall survival (OS) and disease-specific survival (DSS) rates of female patients were significantly higher than those of male patients (OS: 79% vs. 69%, P < 0.001; DSS: 81% vs. 70%, P < 0.001). For patients with locoregionally advanced NPC, the 5-year OS and DSS rates of female vs. male patients were 74% vs. 63% (P < 0.001) and 76% vs. 64%, respectively (P < 0.001). A multivariate analysis showed that gender, age, and TNM stage were independent prognostic factors for the 5-year OS and DSS of NPC patients. The favorable prognosis of female patients is not only attributed to the early diagnosis and treatment but might also be attributed to some intrinsic factors of female patients.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Age Factors , Chemotherapy, Adjuvant , Follow-Up Studies , Nasopharyngeal Neoplasms , Diagnosis , Drug Therapy , Pathology , Radiotherapy , Neoplasm Staging , Prognosis , Radiotherapy, High-Energy , Sex Factors , Survival Rate
5.
Chinese Journal of Cancer ; (12): 342-352, 2013.
Article in English | WPRIM | ID: wpr-295838

ABSTRACT

Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The optimal disease staging system and treatment approaches have not yet been defined. This study aimed to evaluate the prediction of different staging systems for prognosis and treatment options of SCCE. We retrospectively accessed the clinicopathologic characteristics, treatment strategy, and prognosis of 76 patients diagnosed with primary SCCE between 2001 and 2011. The 1-, 2-, 3-, and 5-year overall survival rates were 58%, 31%, 19%, and 13%, respectively. Univariate analysis showed that the 2002 American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) classification (P = 0.002), Veterans Administration Lung Study Group (VALSG) stage (P = 0.001), predisposing factors (P < 0.001), T category (P = 0.023), and M category (P < 0.001) were prognostic factors for overall survival. Multivariate analysis showed that the 2002 AJCC TNM stage (P < 0.001) was the only independent prognostic factor for survival. The value of the area under the receiver operator characteristic (ROC) curve (AUC) of the 2002 AJCC TNM staging system was larger than that of VALSG staging system with regard to predicting overall survival (0.774 vs. 0.620). None of the single treatment regimens showed any benefit for survival by Cox regression analysis. Thus, the 2002 AJCC TMN staging system improved the prediction of SCCE prognosis; however, the optimal treatment regimen for SCCE remains unclear.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Small Cell , Classification , Pathology , Therapeutics , Cisplatin , Combined Modality Therapy , Esophageal Neoplasms , Classification , Pathology , Therapeutics , Esophagectomy , Methods , Etoposide , Lymph Node Excision , Lymphatic Metastasis , Neoplasm Staging , Methods , Paclitaxel , Radiotherapy, High-Energy , Retrospective Studies , Societies, Medical , Survival Rate , United States
6.
Chinese Journal of Cancer ; (12): 502-511, 2013.
Article in English | WPRIM | ID: wpr-320570

ABSTRACT

Neoadjuvant chemotherapy plus radiotherapy is the most common treatment regimen for advanced nasopharyngeal carcinoma (NPC). Whether chronomodulated infusion of chemotherapy can reduce its toxicity is unclear. This study aimed to evaluate the toxic and therapeutic effects of sinusoidal chronomodulated infusion versus flat intermittent infusion of cisplatin (DDP) and 5-fluorouracil (5-FU) followed by radiotherapy in patients with locoregionally advanced NPC. Patients with biopsy-diagnosed untreated stages III and IV NPC (according to the 2002 UICC staging system) were randomized to undergo 2 cycles of sinusoidal chronomodulated infusion (Arm A) or flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy. Using a "MELODIE" multi-channel programmed pump, the patients were given 12-hour continuous infusions of DDP (20 mg/m2) and 5-FU (750 mg/m2) for 5 days, repeated every 3 weeks for 2 cycles. DDP was administered from 10:00 am to 10:00 pm, and 5-FU was administered from 10:00 pm to 10:00 am each day. Chronomodulated infusion was performed in Arm A, with the peak deliveries of 5-FU at 4:00 am and DDP at 4:00 pm. The patients in Arm B underwent a constant rate of infusion. Radiotherapy was initiated in the fifth week, and both arms were treated with the same radiotherapy techniques and dose fractions. Between June 2004 and June 2006, 125 patients were registered, and 124 were eligible for analysis of response and toxicity. The major toxicity observed during neoadjuvant chemotherapy was neutropenia. The incidence of acute toxicity was similar in both arms. During radiotherapy, the incidence of stomatitis was significantly lower in Arm A than in Arm B (38.1% vs. 59.0%, P = 0.020). No significant differences were observed for other toxicities. The 1-, 3-, and 5-year overall survival rates were 88.9%, 82.4%, and 74.8% for Arm A and 91.8%, 90.2%, and 82.1% for Arm B. The 1-, 3-, and 5-year progression-free survival rates were 91.7%, 88.1%, and 85.2% for Arm A and 100%, 94.5%, and 86.9% for Arm B. The 1-, 3-, and 5-year distant metastasis-free survival rates were 82.5%, 79.1%, and 79.1% for Arm A and 90.2%, 85.2%, and 81.7% for Arm B. Chronochemotherapy significantly reduced stomatitis but was not superior to standard chemotherapy in terms of hematologic toxicities and therapeutic response.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma , Cisplatin , Disease-Free Survival , Dose Fractionation, Radiation , Drug Chronotherapy , Fluorouracil , Induction Chemotherapy , Nasopharyngeal Neoplasms , Drug Therapy , Pathology , Radiotherapy , Neoplasm Staging , Neutropenia , Radiotherapy, High-Energy , Stomatitis , Survival Rate
7.
Chinese Journal of Oncology ; (12): 627-631, 2013.
Article in Chinese | WPRIM | ID: wpr-267487

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the method, therapeutic effect and safety of interventional therapy for lung cancer patients with superior vena cava syndrome (SVCS).</p><p><b>METHODS</b>Fifty-two cases of lung cancer with SVCS who received interventional therapy in our hospital between Jan to Dec 2011 were included in this study. Of the 52 cases, 50 cases had successfully carried out superior vena cava stent implantation. The distal venous pressure was measured before and after angioplasty, and the results were assessed by Wilcoxon matched-pairs test. In addition, the 50 patients were followed up and the therapeutic effect and postoperative survival rate were evaluated.</p><p><b>RESULTS</b>The mean distal venous pressure in the 50 patients was significantly decreased from preoperative (28.2 ± 1.9)cm H2O to postoperative (8.7 ± 0.5)cm H2O (P = 0.0085). The efficacy of the treatment was as follows: complete remission (20/52, 38.5%), partial remission (28/52, 53.8%), ineffective 4 (4/52, 7.7%), and total effective rate 92.3%. The complications after angioplasty and stent implantation included chest pain (12 cases, 23.1%), hematoma at the puncture site (5 cases, 9.6%), and fever (2 cases, 3.8%). No serious complications such as massive hemorrhage, pulmonary embolism and stent migration into the cardiac atrium were observed. The rate of postoperative restenosis was low (2/52, 3.8%). For the SCLC group, the objective effective rate was 74.1% and 1-year survival rate was 21.0%. For the NSCLC group, the objective effective rate was 21.7% and 1-year survival rate was 35.0%.</p><p><b>CONCLUSIONS</b>For lung cancer patients with SVCS, interventional therapy may relief obstruction effectively, promote blood flow recovery, and relieve clinical symptoms. Interventional therapy with endovascular angioplasty and stenting may be highly recommended as the first choice for palliative treatment of SVCS. It is an effective initial palliative treatment. However, subsequent comprehensive anti-tumor treatment is necessary.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Angioplasty , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Blood Pressure , Carcinoma, Non-Small-Cell Lung , Drug Therapy , Radiotherapy , Chest Pain , Follow-Up Studies , Hematoma , Lung Neoplasms , Drug Therapy , Radiotherapy , Radiotherapy, High-Energy , Remission Induction , Small Cell Lung Carcinoma , Drug Therapy , Radiotherapy , Stents , Superior Vena Cava Syndrome , Therapeutics , Survival Rate
8.
Chinese Journal of Oncology ; (12): 873-876, 2012.
Article in Chinese | WPRIM | ID: wpr-284267

ABSTRACT

<p><b>OBJECTIVE</b>To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma.</p><p><b>METHODS</b>A total of 154 cases in the stage of cT3N0-1M0 were randomly assigned to two arms. The arm A received 2 cycles of doctaxel 75 mg/m(2) plus cisplatin 25 mg/m(2) d1-3 and 40 Gy of radiation therapy, and the arm B received 2 cycles of cisplatin 25 mg/m(2) d1-3 plus fluorouracil 600 mg/m(2) d1 ∼ 5 and 40 Gy of radiation therapy. The surgery was performed 3 - 4 weeks later.</p><p><b>RESULTS</b>Grade 3/4 toxicities occurred in 53.2% of the patients in arm A and in 36.4% of the patients in arm B (P = 0.035). Neutropenia occurred in 20.7% of the patients in arm A and 5.6% of the patients in arm B (P = 0.004). Nine patients aborted surgery due to tumor progression. 71 patients underwent resection in 73 cases of the arm A and 69 patients underwent complete resection, 70 patients underwent resection in 72 cases and 70 complete resection of the arm B, respectively (P > 0.05). No mortality was noted. The overall complication rate was similar in the two arms (21.9% vs. 23.6%). Pathological complete response was achieved in 27 patients (35.1%) in the arm A and 16 patients (20.8%) in the arm B (P = 0.048).</p><p><b>CONCLUSIONS</b>Neoadjuvant chemoradiotherapy with docetaxel plus cisplatin can be well tolerated and achieves a higher pathological complete response rate than with cisplatin plus fluorouracil.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Squamous Cell , Pathology , General Surgery , Therapeutics , Chemoradiotherapy , Cisplatin , Esophageal Neoplasms , Pathology , General Surgery , Therapeutics , Fluorouracil , Neoadjuvant Therapy , Neoplasm Staging , Neutropenia , Radiotherapy, High-Energy , Remission Induction , Taxoids , Vomiting
9.
Chinese Journal of Oncology ; (12): 356-359, 2012.
Article in Chinese | WPRIM | ID: wpr-335280

ABSTRACT

<p><b>OBJECTIVE</b>The primary aim of this prospective study was to use serial (18)F-FDG PET-CT imaging to evaluate the trend of the tumor's maximum standardized uptake value (SUVmax) during radiotherapy (RT) for patients with nasopharyngeal carcinoma (NPC), and to explore the possibility of early evaluation of the tumor bio-metabolic response during radiotherapy.</p><p><b>METHODS</b>Sixty patients with biopsy-proven primary NPC were prospectively enrolled into the study. All patients underwent four (18)F-FDG PET-CT scans: one initial scan before RT/cisplatin based concurrent chemoradiotherapy, at the point of 50 Gy during RT, the end of RT, and one month after RT, respectively. Tumor (18)F-FDG uptake was analyzed according to the World Health Organization pathological type.</p><p><b>RESULTS</b>There was a significant difference (P < 0.001) of the mean of SUVmax of the primary site among pretreatment (11.20 ± 5.37) and posttreatment at the dose of 50 Gy (3.50 ± 1.59), at the end of RT (3.05 ± 1.56) and one month after RT (2.52 ± 1.46). There was also a significant difference (P < 0.001) of the mean of SUVmax of neck node site. However, there was a significant difference of the SUVmax between histological WHO type IIb and type IIa in the primary site (P = 0.046) [(67 ± 19)% reduction at dose 50 Gy for type IIb vs. (55 ± 24)% for type IIa] but not in the lymph nodes.</p><p><b>CONCLUSIONS</b>Early PET scan during or right after RT instead of conventional 3 months interval after RT is indicated to evaluate the tumor response and to develop individualized adaptive radiotherapy in NPC. Our next study will attempt to demonstrate the results based on long-term follow-up data.</p>


Subject(s)
Female , Humans , Male , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Squamous Cell , Diagnosis , Drug Therapy , Pathology , Radiotherapy , Chemoradiotherapy , Cisplatin , Fluorodeoxyglucose F18 , Lymphatic Metastasis , Nasopharyngeal Neoplasms , Diagnosis , Drug Therapy , Pathology , Radiotherapy , Neoplasm Staging , Positron-Emission Tomography , Methods , Prospective Studies , Radiopharmaceuticals , Radiotherapy Dosage , Radiotherapy, High-Energy , Radiotherapy, Intensity-Modulated , Tomography, X-Ray Computed
10.
Chinese Journal of Oncology ; (12): 305-307, 2011.
Article in Chinese | WPRIM | ID: wpr-303328

ABSTRACT

<p><b>OBJECTIVE</b>Breast conserving surgery (BCS) is one of standard treatment approaches in early breast cancer. Although most defect after BCS can be repaired, the cosmetic outcomes are unsatisfactory in the patients with poor tumor/breast ratio. Oncoplastic surgery (OPS) has emerged as a new approach for providing adequate tumor resection without compromise of aesthetic outcomes in BCS. Our purpose is to explore the cosmetic outcomes of applying latissimus dorsi (LD) muscle flap to reshape severe breast conservation deformities in breast cancer.</p><p><b>METHODS</b>Totally 24 cases of breast cancer were studied. The tumor size was 3.0 - 5.5 cm (median 3.5 cm). All the cases underwent BCS and achieved negative margin by frozen sections examination. Then LD flap reshaping were performed. All the patients received whole breast radiotherapy ± chemotherapy ± endocrine therapy.</p><p><b>RESULTS</b>All the LD flaps were alive without skin necrosis. After a median 23-month follow-up, all the cases were disease-free surviving. The whole breast radiotherapy had no significant effect on the LD flaps. The rate of good cosmetic results was 79.2%. The subjective satisfactory rate of the patients was 96%.</p><p><b>CONCLUSIONS</b>Both satisfactory aesthetic outcome and good treatment effect were obtained using LD flap to reshape severe breast conservation deformity. OPS offers tools for breast conservation in patients otherwise destined for mastectomy or poor aesthetic outcome, such as large tumor/breast ratio, nipple-areola complex tumor, ductal carcinoma in situ, neoadjuvant chemotherapy cases and so on.</p>


Subject(s)
Adult , Female , Humans , Middle Aged , Breast Neoplasms , Drug Therapy , Radiotherapy , General Surgery , Carcinoma, Ductal, Breast , Drug Therapy , Radiotherapy , General Surgery , Carcinoma, Intraductal, Noninfiltrating , Drug Therapy , Radiotherapy , General Surgery , Chemotherapy, Adjuvant , Follow-Up Studies , Mammaplasty , Methods , Mastectomy, Segmental , Methods , Muscle, Skeletal , Transplantation , Patient Satisfaction , Radiotherapy, High-Energy , Methods , Surgical Flaps
11.
Chinese Journal of Oncology ; (12): 629-631, 2011.
Article in Chinese | WPRIM | ID: wpr-320155

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the early efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer.</p><p><b>METHODS</b>Forty-two cases of cervical cancer (FIGO IIb to IVa) were divided randomly into two groups: radiotherapy alone (21 cases) and radiation plus chemotherapy (Nedaplatin) group. The same radiotherapy was given to the two groups. Patients of the RT + C group received nedaplatin 30 mg/m2 in intravenous drip infusion once weekly on day 1, for 4 to 5 weeks, and megestrol 160 mg orally every day during the radiation therapy.</p><p><b>RESULTS</b>The early outcome: the complete remission rate was 81.0% and partial remission rate was 19.0% in the RT + C group, significantly better than the CR (38.1%) and PR (42.9%) in the RT group. The 1-year survival rates in the two groups were 100% (21/21) and 81.0% (17/21), respectively, with a significant difference between the two groups (P<0.05).</p><p><b>CONCLUSIONS</b>The combination of nedaplatin and megestrol with concurrent chemoradiotherapy can improve the early outcome of advanced cervical cancer, with somewhat increased but tolerable adverse effects.</p>


Subject(s)
Adult , Female , Humans , Middle Aged , Adenocarcinoma , Drug Therapy , Pathology , Radiotherapy , Alopecia , Anemia , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Brachytherapy , Chemoradiotherapy , Diarrhea , Follow-Up Studies , Iridium Radioisotopes , Therapeutic Uses , Leukopenia , Megestrol , Neoplasm Staging , Organoplatinum Compounds , Particle Accelerators , Radiotherapy, High-Energy , Remission Induction , Survival Rate , Thrombocytopenia , Uterine Cervical Neoplasms , Drug Therapy , Pathology , Radiotherapy
12.
Chinese Journal of Oncology ; (12): 925-928, 2011.
Article in Chinese | WPRIM | ID: wpr-335361

ABSTRACT

<p><b>OBJECTIVE</b>The aim of this paper was to evaluate the treatment outcome of multimodal treatment for 196 patients with locoregional recurrent esophageal cancer after curative treatment and to determine the prognostic factors of recurrence.</p><p><b>METHODS</b>One hundred and ninety six patients with locoregional recurrent esophageal cancer curatively treated in our hospital were included in this study. Kaplan-Meier method was used to analyze the survival rate. Log rank test was used to evaluate the difference between the groups. Multivariate survival analysis was conducted using a Cox proportional hazard regression model with a backward stepwise procedure.</p><p><b>RESULTS</b>The overall 1-, 2- and 3-year survival rates were 29.8%, 5.9% and 4.0%, respectively, with a median survival time of 8.0 months. The univariate analysis showed that ECOG PS, the interval between initial treatment and recurrence, the regimens of initial treatment and retreatment were independent prognostic factors. The multivariate analysis showed that the regimens of initial treatment and retreatment were independent prognostic factors. Retreatment methods significantly influenced the survival. The median survival time of chemoradiotherapy, radiation therapy alone, chemotherapy alone, EGFR-TKI and best supportive care were 13.0, 7.0, 6.0, 4.0 and 3.0 months, respectively (P = 0.000).</p><p><b>CONCLUSIONS</b>The prognosis of patients with locoregional recurrent esophageal cancer after curative treatment is poor. The main prognostic factors are the regimens of initial treatment and retreatment. Multimodal treatment including radiotherapy and chemotherapy may improve the long-term survival of the patients.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Squamous Cell , Therapeutics , Chemoradiotherapy , Combined Modality Therapy , Esophageal Neoplasms , Therapeutics , Esophagectomy , Methods , Follow-Up Studies , Neoplasm Recurrence, Local , Therapeutics , Proportional Hazards Models , Radiotherapy, High-Energy , Retrospective Studies , Survival Rate
13.
Chinese Journal of Oncology ; (12): 132-138, 2010.
Article in Chinese | WPRIM | ID: wpr-260452

ABSTRACT

<p><b>OBJECTIVE</b>The extrapulmonary small cell carcinoma (EPSCC), a uncommon malignant tumor, has seldom been reported. The aim of this study was to analyze the clinical characteristics, treatment and prognosis of EPSCC.</p><p><b>METHODS</b>The clinical data of 243 patients admitted in our hospital from 1977 to 2007 were reviewed. The survival rate was calculated by the Kaplan-Meier method and log-rank test.</p><p><b>RESULTS</b>The median age of the patients was 58 years and the male-to-female ratio was 2.47:1. According to VALSG criteria, 209 patients had limited disease (LD) and 34 had extensive disease (ED). 170 patients received chemotherapy-based multimodal therapy, 73 received surgery, and/or radiotherapy. The 6, 12, 24, 36 and 60-month survival rates of these patients were 88.9%, 67.2%, 36.8%, 27.3% and 18.3%, respectively. The clinical stage, vessel involvement and regional lymph node metastases were independent prognostic factors of EPSCC. Patients with LD had a median overall survival of 18.6 months compared with 14.0 months in patients with ED (P = 0.030). The median survival was 19.2 months for the patients without vessel involvement and 14.4 months with vessel involvement (P = 0.026). The median survival of the patients with regional lymph node metastases was 13.9 months, while 39.5 months without regional lymph node metastases (P = 0.000). Among different primary sites, patients with gynecologic small cell cancer had a median survival of 28.0 months, head and neck 20.1 months and gastrointestinal tract 14.3 months. Brain metastasis was observed in a lower number of patients with EPSCC compared with that in patients with SCLC. There were no statistically significant differences in overall survival between patients with pure and mixed EPSCC (P = 0.396).</p><p><b>CONCLUSION</b>EPSCC is an uncommon malignant tumor with early metastasis and poor prognosis. The clinical characteristics of EPSCC and SCLC were similar in some aspects, however, there are some differences in etiology, clinic course, survival and frequency of brain metastases. These differences may influence the choice of therapeutic strategy. Multimodal therapy, combination of chemo- and radio-therapy after surgical resection may improve the outcome of EPSCC.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Small Cell , Pathology , General Surgery , Therapeutics , Cisplatin , Therapeutic Uses , Combined Modality Therapy , Disease-Free Survival , Esophageal Neoplasms , Pathology , General Surgery , Therapeutics , Etoposide , Therapeutic Uses , Follow-Up Studies , Gastrointestinal Neoplasms , Pathology , General Surgery , Therapeutics , Head and Neck Neoplasms , Pathology , General Surgery , Therapeutics , Lung Neoplasms , Lymphatic Metastasis , Neoplasm Staging , Radiotherapy, High-Energy , Survival Rate , Urogenital Neoplasms , Pathology , General Surgery , Therapeutics
14.
Chinese Journal of Oncology ; (12): 199-202, 2010.
Article in Chinese | WPRIM | ID: wpr-260437

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the clinicopathologic characteristics, therapy and prognostic factors of small cell carcinoma of the uterine cervix (SCCC).</p><p><b>METHODS</b>Nine patients with SCCC underwent radical hysterectomy at the Cancer Hospital of CAMS between 2000 to 2009. Clinical and pathological data were analyzed, and the related literature was reviewed.</p><p><b>RESULTS</b>The average age of 9 patients was 41 years old. Irregular vaginal bleeding and postcoital spotting were the most common symptoms. According to FIGO staging criteria, six patients were stage Ib1 disease, 2 stage Ib2 and 1 stage IVb. All tumors were composed of small-sized cells with scant cytoplasm, darkly stained round to oval nuclei, finely dispersed chromatin and absence of nucleoli. High mitotic activity and lymphovascular invasion were also common findings. Immunohistochemical staining showed at least three neuroendocrine markers (NSE, CgA, Syn and CD56) were positive in each case. All patients received postoperative chemotherapy, with or without radiotherapy. Seven patients remained alive 6 to 104 months and one died 14 months postoperatively.</p><p><b>CONCLUSION</b>SCCC is a highly malignant tumor with aggressive behavior. Correct diagnosis of SCCC depends on the combination of light microscopic and immunohistochemical analysis. It is necessary to use multimodality treatment for SCCC, especially the chemotherapy. However, the prognosis is dismal.</p>


Subject(s)
Adult , Female , Humans , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , CD56 Antigen , Metabolism , Carcinoma, Small Cell , Metabolism , Pathology , Therapeutics , Chromogranin A , Metabolism , Cisplatin , Therapeutic Uses , Combined Modality Therapy , Cyclin-Dependent Kinase Inhibitor p16 , Metabolism , Follow-Up Studies , Hysterectomy , Methods , Lymph Node Excision , Neoplasm Staging , Nuclear Proteins , Metabolism , Paclitaxel , Phosphopyruvate Hydratase , Metabolism , Radiotherapy, High-Energy , Survival Rate , Synaptophysin , Metabolism , Taxoids , Therapeutic Uses , Thyroid Nuclear Factor 1 , Transcription Factors , Metabolism , Uterine Cervical Neoplasms , Metabolism , Pathology , Therapeutics
15.
Chinese Journal of Oncology ; (12): 290-293, 2010.
Article in Chinese | WPRIM | ID: wpr-260415

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the clinicopathological characteristics and treatment of adenoid cystic carcinoma of the Bartholin gland.</p><p><b>METHODS</b>The clinicopathological data of six patients with adenoid cystic carcinoma of the Bartholin gland were retrospectively analyzed. The median age was 40.8 years (range 30 to 54 years). Surgery was the primary treatment. Simple vulvar tumor resection was performed in 1 patient. Four cases underwent radical vulvectomy with bilateral inguinal lymph node dissection and 1 case underwent wide local excision of the vulva with bilateral inguinal lymph node biopsy. Two cases with high risk factors received postoperative radiotherapy.</p><p><b>RESULTS</b>All patients had definite pathological diagnosis. Cribriform arrangement of tubules and gland-like elements and infiltration of perineural spaces were two main microscopic features of this type of tumor. The pathological examination after surgery revealed that two patients had positive surgical margins, one had negative margin, 1 adjacent to the tumor and 1 unknown; 5 cases had negative inguinal lymph nodes and 1 unknown. All the 6 patients were followed-up. Recurrence developed in 4 cases including 3 with both local recurrence and lung metastasis, and one had lung metastasis only. One patient died of lung metastasis and her total survival period was 135 months. The other 3 recurrent patients survived with tumor and the total survival period was 241, 128 and 103 months, respectively. Two cases without recurrence survived 8 and 121 months, respectively.</p><p><b>CONCLUSION</b>Adenoid cystic carcinoma of the Bartholin gland is a slow growing but locally very aggressive neoplasm with a high capacity for local recurrence and lung metastasis. Surgery is the most common and useful treatment. Radiation is a choice of treatment for patients with high risk factors after surgery such as positive surgical margin, deep local invasion and infiltration of perineural spaces or for recurrent patients without opportunity of excision.</p>


Subject(s)
Adult , Female , Humans , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Bartholin's Glands , Pathology , General Surgery , Carcinoma, Adenoid Cystic , Pathology , Radiotherapy , General Surgery , Combined Modality Therapy , Follow-Up Studies , Lung Neoplasms , General Surgery , Lymph Node Excision , Lymphatic Metastasis , Neoplasm Recurrence, Local , Drug Therapy , Radiotherapy , General Surgery , Radiotherapy, High-Energy , Retrospective Studies , Survival Rate , Vulva , General Surgery , Vulvar Neoplasms , Pathology , Radiotherapy , General Surgery
16.
Chinese Journal of Oncology ; (12): 452-455, 2010.
Article in Chinese | WPRIM | ID: wpr-260379

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the role of postoperative chemoradiotherapy (CRT) as a multimodality treatment option for locally advanced thoracic esophageal squamous cell carcinoma (ESCC) by a prospective comparison between surgery alone and postoperative CRT.</p><p><b>METHODS</b>Using preoperative computed tomography (CT)-based staging criteria, 158 patients with ESCC (stage II-III) were enrolled in this prospective study. With informed consent, the patients were randomized into two groups: postoperative CRT (78 cases) and surgery alone (S, 80 cases). After a few minor adjustments to the enrolled patients, the actual patients of postoperative CRT group and S group were 74 cases and 77 cases, respectively. Comparison of the complications, local recurrence rate, distant metastasis rate, survival rate and progression-free survival in the two groups was carried out.</p><p><b>RESULTS</b>With a median follow-up of 37.5 months, the 1-, 3-, 5-, 10-year overall survival (OS) rates were 91.0%, 62.8%, 42.3%, 24.4% and 87.5%, 51.3%, 33.8%, 12.5% for the postoperative CRT and S arm, respectively. A significant difference in OS was detected between the two arms (P = 0.0276). There was a significant difference of progression-free survival (PFS) between the two arms (P = 0.0136). The local recurrence rates in the postoperative CRT group and S group were 14.9% and 36.4%, respectively (P < 0.05). No significant difference was detected between the complications of the two groups (P > 0.05). Toxicities of chemoradiotherapy in the postoperative CRT arm were moderate, which can be relieved rapidly by adequate therapy.</p><p><b>CONCLUSION</b>Rational application of postoperative chemoradiotherapy can provide a benefit in progression-free survival and overall survival in patients with locally advanced esophageal squamous cell carcinoma.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Squamous Cell , Pathology , Therapeutics , Chemotherapy, Adjuvant , Cisplatin , Disease-Free Survival , Esophageal Neoplasms , Pathology , Therapeutics , Esophagectomy , Methods , Follow-Up Studies , Lymph Node Excision , Lymphatic Metastasis , Neoplasm Recurrence, Local , Neoplasm Staging , Paclitaxel , Prospective Studies , Radiotherapy, Adjuvant , Radiotherapy, High-Energy , Survival Rate
17.
Chinese Journal of Medical Instrumentation ; (6): 94-96, 2010.
Article in Chinese | WPRIM | ID: wpr-281154

ABSTRACT

This article presents and discusses some special problems about the dose calibration of high-energy elections for Linear Accelerator according to the practice of the authors. Thus the paper explain the issues of this work, and clarify the wrong understanding of real work for the aim of attaining the rules of quality assurance in radiotherapy by WHO.


Subject(s)
Calibration , Particle Accelerators , Radiotherapy Dosage , Radiotherapy, High-Energy , Methods
18.
Chinese Journal of Oncology ; (12): 614-618, 2010.
Article in Chinese | WPRIM | ID: wpr-293504

ABSTRACT

<p><b>OBJECTIVE</b>To analyze the clinical features and prognostic factors of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) and to evaluate the staging system and treatment modality of PG-DLBCL.</p><p><b>METHODS</b>The clinicopathological data of 69 patients with PG-DLBCL were retrospectively analyzed. Event-free survival (EFS) and overall survival (OS) were the primary endpoints.</p><p><b>RESULTS</b>The EFS rates at 1, 3, and 5 years were 83.8%, 71.1%, and 69.0%, respectively, with a mean EFS of 91.3 months. The 1-, 3-, and 5-year OS rates were 91.3%, 80.3%, and 72.4%, respectively, with a mean OS of 98.8 months. Univariate analysis revealed that either EFS or OS was significantly prolonged by the following factors (P < 0.05): modified Ann Arbor stage I(E) or II(E1) disease; normal lactate dehydrogenase (LDH) level; normal hemoglobin level; normal albumin level; International Prognostic Index (IPI) of 0 or 1; tumor size < 5 cm; and less depth of invasion. While gender, age, B symptoms at presentation, performance status and treatment modality were not significantly associated with the prognosis (P > 0.05). Cox regression model revealed that only modified Ann Arbor stage and albumin level were independent prognostic factors for EFS and OS.</p><p><b>CONCLUSION</b>The most accurate staging system and the exact role of different therapeutic options for PG-DLBCL are still debated. Further randomized prospective studies with a large number of patients are still needed to establish an optimal management for this disease.</p>


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Albumins , Metabolism , Antibodies, Monoclonal, Murine-Derived , Therapeutic Uses , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Combined Modality Therapy , Cyclophosphamide , Therapeutic Uses , Disease-Free Survival , Doxorubicin , Therapeutic Uses , Follow-Up Studies , Gastrectomy , Methods , Hemoglobins , Metabolism , L-Lactate Dehydrogenase , Blood , Lymphoma, Large B-Cell, Diffuse , Blood , Pathology , Therapeutics , Neoplasm Invasiveness , Neoplasm Staging , Prednisone , Therapeutic Uses , Proportional Hazards Models , Radiotherapy, High-Energy , Retrospective Studies , Rituximab , Stomach Neoplasms , Blood , Pathology , Therapeutics , Survival Rate , Vincristine , Therapeutic Uses
19.
Chinese Journal of Cancer ; (12): 668-676, 2010.
Article in English | WPRIM | ID: wpr-296371

ABSTRACT

<p><b>BACKGROUND AND OBJECTIVE</b>The role of postmastectomy radiotherapy (PMRT) in breast cancer patients with T1-T2 tumors and 1-3 positive axillary nodes is still uncertain. This study investigated the value of PMRT for these patients.</p><p><b>METHODS</b>In the retrospective data of 488 eligible patients, survival analysis was performed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using a log-rank test and the Cox proportional hazards model, respectively.</p><p><b>RESULTS</b>The median observation time was 54 months. The 5- and 10-year locoregional recurrence-free survival (LRFS) rates were 90.8% and 86.9%, respectively. The 5- and 10-year disease-free survival (DFS) rates were 82.0% and 74.3%, respectively. The 5- and 10-year overall survival (OS) rates were 90.7% and 82.7%, respectively. For the 412 patients without PMRT, T2 classification, 2-3 positive nodes, and hormone (estrogen and progesterone) receptor-negative were risk factors for locoregional recurrence in the multivariate analysis. On the basis of these 3 risk factors, the group with 2-3 factors had a 10-year LRFS rate of 63.1% compared with 96.1% for the group with 0-1 factors (P < 0.001). For the group with 2-3 risk factors, LRFS and DFS were significantly improved by PMRT, with the 5- and 10-year LRFS rates without PMRT of 82.4% and 63.1%, respectively, and, with PMRT, of 98.1% at both 5 years and 10 years (P = 0.002). The 5- and 10-year DFS rates without PMRT were 72.0% and 57.6%, respectively, and, with PMRT, the 5- and 10-year DFS rates were 89.4% and 81.7%, respectively (P = 0.007). There was no significant difference in the 10-year OS rates between patients with and without PMRT. However, there is the potential benefit of 15.3% (87.1% vs. 71.8%, P = 0.072). Conversely, the group with 0-1 factors of PMRT had no effect on prognosis.</p><p><b>CONCLUSIONS</b>In patients receiving mastectomy with T1-T2 breast cancer with 1-3 positive nodes, for the group with 2-3 risk factors, PMRT significantly improved LRFS and DFS and has potential benefit in OS.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Young Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Breast Neoplasms , Drug Therapy , Pathology , Radiotherapy , General Surgery , Carcinoma, Ductal, Breast , Drug Therapy , Pathology , Radiotherapy , General Surgery , Carcinoma, Lobular , Drug Therapy , Pathology , Radiotherapy , General Surgery , Chemotherapy, Adjuvant , Disease-Free Survival , Lymphatic Metastasis , Mastectomy , Neoplasm Recurrence, Local , Neoplasm Staging , Radiotherapy, Adjuvant , Radiotherapy, High-Energy , Receptors, Estrogen , Metabolism , Receptors, Progesterone , Metabolism , Retrospective Studies , Risk Factors , Survival Rate
20.
Chinese Journal of Cancer ; (12): 787-795, 2010.
Article in English | WPRIM | ID: wpr-296353

ABSTRACT

<p><b>BACKGROUND AND OBJECTIVE</b>Nasopharyngeal carcinoma (NPC) is known for its propensity for distant metastases. Lung metastasis is one of the most important causes of death for patients with NPC. Solitary metastatic lung tumor from NPC is a distinctive group associated with a better survival. This study was to find a more effective treatment modality and prognostic factors for the group.</p><p><b>METHODS</b>Clinical data of 105 cases of solitary metastatic lung tumor from NPC were retrospectively analyzed. Survival rate was calculated by the Kaplan-Meier method. The difference of survival between the patients treated by different modalities was evaluated by the log-rank test. The Cox univariate and multivariate analyses of gender, age, pathologic type, stage, adjuvant chemotherapy, evaluation of treatment for NPC, disease-free interval, size of metastatic tumor, pulmonary hilar and/or mediastinal lymph node metastasis, treatment modalities, recurrent distant metastases and/or relapse of NPC were conducted.</p><p><b>RESULTS</b>The local control rate was 53.8% in chemotherapy group, 88.0% in radiotherapy ± chemotherapy group, and 96.4% in operation ± chemotherapy group (P < 0.01). The most promising progression-free survival (PFS) and overall survival (OS) were obtained with operation ± chemotherapy and followed by radiotherapy ± chemotherapy. Both of them showed much better efficacy than chemotherapy (P < 0.001). The Cox multivariate analysis showed that recurrent distant metastases and/or relapse of NPC affected the survival (OR = 2.087, 95% CI = 1.277-3.410, P = 0.003). The T stage of NPC, size of metastatic tumor, hilar and/or mediastinal lymph node metastasis, and the treatment modality were independent prognostic factors.</p><p><b>CONCLUSIONS</b>Operation ± chemotherapy and radiotherapy ± chemotherapy are better treatment of solitary metastatic lung tumor from NPC, which could improve the local control and prolong the PFS and OS. Chemotherapy is recommended for patients with higher T stage of NPC, size of metastatic tumor ≥ 3 cm, pulmonary hilar and/or mediastinal lymph node metastasis.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Squamous Cell , Therapeutics , Combined Modality Therapy , Disease-Free Survival , Follow-Up Studies , Lung Neoplasms , Therapeutics , Lymphatic Metastasis , Nasopharyngeal Neoplasms , Pathology , Neoplasm Recurrence, Local , Neoplasm Staging , Pneumonectomy , Methods , Radiotherapy, High-Energy , Remission Induction , Retrospective Studies , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL